Ardelyx reported $240.77M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.


Ordinary Share Capital Change Date
Abbott USD 25.12B 28M Mar/2025
Amgen USD 538M 33.04B Jun/2025
Ardelyx USD 240.77M 240.74M Jun/2025
Corcept Therapeutics USD 105.29M 105.15M Jun/2025
Life Technologies USD 92.87M 92.79M Jun/2025
Sanofi 1.22B 36.5M Jun/2025
TG Therapeutics USD 158.02M 157.87M Jun/2025
United Therapeutics USD 45.22M 44.42M Jun/2025